Home » Pluristem Doses First Patient in Phase I Trial for Treatment of Peripheral Artery Disease
Pluristem Doses First Patient in Phase I Trial for Treatment of Peripheral Artery Disease
Pluristem Therapeutics Inc. said it dosed the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, in a Phase I clinical trial for the treatment of critical limb ischemia, the end-stage of peripheral artery disease.
RTTNews
RTTNews
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May